’5 dr life habeebullah sciences · 2018. 11. 14. · requirements) regulations, 2015 ref:...
TRANSCRIPT
’5 Dr Habeebullaha Life Sciences
T0: Date: 12/11/2018
1) BSE timited
PJ. Towers, Dalal Street,
Mumbai — 400 001
2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4fn floor, Plot No C 62, Opp‘ Trident Hotel,
Sandra Kurla Complex, Sandra (E), Mumbai — 400 098
3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Oppl Sahajanand College,
Panjara Pole, Ambawadi. Ahmedabad - 380 015
u
Sub: Outcome of Board Meeting under Regulation 30 81 33 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015
Ref: Company’s Letter dated Wednesday, 31“ October, 2018
We wish to inform you that the Board of Directors of the Company. at its meeting held today i.e., Monday,
12".1 November, 2018 at Registered Office, have considered and approved inter-alia, the following
1. Standalone UnAAudited Financial Results for Quarter 11 and Half Year Ended 30‘h September, 2018
2. Statement of Assets and Liabilities for Half Year Ended 30‘h September, 2018
3. Limited Review Report for Quarter 11 and Half Year Ended 30th September, 2018 issued by
M/s. MSKA & Associates, Statutory Auditors of the Company.
The meeting commenced at 3.00 PM and concluded at 4.00 PM.
Request you take the same on records,
Thanking you‘
For DR HABEEBULLAH LIFE SCIENCES LIMITED
7:?“K. Krishnam Raju
Encl: as above
Regd.()fi 2
Corp Off : Ni
Dr Habeebullah Life Sciences Ltd(Formerly Known as PC Products India Limited)
5-36/1?th Dil, Chintalmet X Roads, Upperpally. Rajet‘idra Nagar Mandel, l'lyderabad , 500048l 'l‘S.lndia
0.] Phase I. Vasudcva‘s Bloomfield Elation. Khajaguda, Nanakramgudm Hyderabad - 50000818, India
CIN No. : L851]0TGI996PLC099198 Email : inibl’adrhlslxom, pcpmductsindial’ciagmaiLComContact No.: 040 ~ 2970 3333. +91 9030057370 Website : wwwdrhlslcom
|||>
‘lli
Life Sciences
PAR“ ) Rs in lekns
SFANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER il AND HALF VEAR ENDED 30m SEPTEMBER, 2013
Particulars QUARTER ENDED Half Year ended' '
Yearended 31
3 Months corresponding 3 Preceeding 3 Half year ended Half year ended 03-2018
ended months ended in morm‘is ended 30—09-2018 3009-2017S'Na
30—09-2018 previous year 30-05—2018
3009-2017
UnAud‘rted anAndited UnAudited unAudited UnAudited Audited
1 Revenue from Operations 52.92 14.95 30.45 03.30 17.50 61.67
li other income— - 1 . » -
iii Total Revenue (M!) 52.92 14.95 30.46 33.30 17.50 61.67
lV Expenses
Cost of Material Consumed 4.95 0.50 3.11 3.07 0.56 6.41
Purchase ofSiocka'nrtrade .. .
- — -
Changes in inventories of finished goods, Work in - - - - - -
Droizress and Stock in trade- » - . ~ -
Employee benefits expense 31.29 17.02 34.37 65.66 40.01 37.42
Finance Costs. . .
—.
Depreciation and Amanisatipn expense 0.09 . 0.09 0.15 — 0.23
Professional Charges 14.43 . 10.81 25.24 .
Other Expenses 50.717 6.287 44.85 105.55
7 17.45 7 7
53.77
Total Expenses 11.1.45 24.66 93.23 204.71 53.02 155.02
v Pruitt/(mas) from before Exceptional items and tax
((.iv) (55.55) (9.71) (52.77) (12133) (40.52) (102.15)
Vl Exceptional Items. - - —
.
Vii Profit/(toss) before m (v40) (58.50) (9.71) (51.77) (12133) (40.52) (102.15)
vm Tax Expense:- . - - - -
Current Tax
'
. » - . - -
Deferred Tax- - - . . .
IX Profit] (Loss) for the period from Continuing
operations (Vii-Vila) (53.55) (9.71) (62.77) (121.33) (40.52) (102.15)
)1 Profit] (Loss) from discontinuing operations . . . . . .
Xi Tax Expense of discontinuing operations . . _ . . .
Xil Profit] (Loss) for the period from discontinuing
operations after tax (X-Xl) . . . _ . _
XI" Pmfit/ (LOSS) for Ihe periad (lX+XII) [53.56) (9.71) (62.77) (121.33) (40.52) (102.15)
Xi'v‘ other Comprehensive income
A) (i) items that will not he reclassified to profit or
loss
(ii) Income Tax related to items that will not be
relciassified to profit or 1055 B)
(i) items that will be reciassiied to profit or ioss
(ii) Income Tax relating to items that will be
re£i§5€i gd to nmfrr or In“1 - . e . .
XV Total Comprehensive income for the periad
(xiilexw) (Comprising Pmfit (loss) and Other
Comprehensive Income for the Period) (58.56) (9.71) (62.77) (12133) (40.52) (102.15]
XVI Earnings Per Equity snare Ire: Continuing
Operations) (Face Value imt 10/- each)
2) Basic (0.49) (0.09) (0.53) (1.02) (0.40) (0.96)
z) Diluted (0.40) (0.09) (0.45) (0.04) (0.40) (0.74)
XVII Earnings Per Equity Share (For Discontinued
Operations) (Face Value NR 10/- each)
1) Basie
2) Diluted
xvm Earnings Per Equity Share (Formminued and
Discontinued 0perations)(Face Value [NR 10/.
each) 1)
Basic (0.49) (0.09) (0.53) (0.98) (0.40) (0.95)
2) Diluted (0.40) (0.09) (0.45) (001) (0.40) (0.74)
Xix Paid Up Equity Share Capital (Face Value arm 10/
per share) 1,221.37 1025.37 1,221.37 1,221.37 1025.37 1175.07
XX Raerves excluding Revaluation memes
as per balance sheet of previous
W (142.23) (190.07) (142.23) (142.23) (190.07) (142.23)
Dr Habeebullah Life Sciences Ltd(Formerly Known as PC Products India Limited)
chd.()fi' : 2—5—36/(‘LRD/1. Chlnlulmcl X Roads. Upperpaiiy, Rajendl'a Nagal' Manda]. Hyderabad - 500043. TSJndia
Corp 011' 0.1 1. Pilzise i. \/'asud0\ 0’s Bioomfield Elation. Khajaguda. Nanakmmgudu. Hyderabad — SOOOUETS. India
CIN N). : 1.85 i HiTGi‘WéPLCOQQiQS Email : iniblk2;(il'llisl.00ili. pcprodilctsilidialiirgmai1.00m(30111001 N0; 040 - 2970 3333, +91 9030057370 Website : wwsi‘xirh151.com
Dr Habeebuflah
"é; Dr Habeebullahé Life Saences
Notes:
1 The Unaudited Standalone finanaal results for the Quarter Ii and period ended 30, September 2013 were reviewed and recommended by the Audit Committee
and approved by the Board of Directors at its meeting held on November 12, 2013. The Statutory Auditors have otrried out the Limited Review ofthe
Unaudited Standalone financial Results in accordance with Regulation 33 of SEEI lLODR) Regulations, 2015).2 The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in
Indian Accounting Standards {IND ASl 34 interim Financial Reporting proscribed under section 133 ufthe Companies Act, 2013 ("the Act“) read wnh relevant
rules issued thereunder, other accounting principles generally aocepted in india and guidelines issued by Securities and Exchange Board oi lndia(“SEBl"l and
Regulation 33 of 5551 (max) Regulations, 2015 am: sEal Circular dated 05th July, 2016.
3 Adoption of ind AS 115 . Revenue from contracts with customers
Effective April 1, 2018, the Company has adopted lnd AS 115 ”Revenue from Contracts with Customers” using the cumulative catchrup transition method
which is applied to contracts that were nut completed as of April 1, 2018. Accordingly, the comparatives have nut been retrospectively adjusted. The effect an
adoption of Ind AS 135 was insignificant on thefiiiancial statements.
4 The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" Le, Health Care Sector Hence, the separate disclosure on
Segment information is not required.
The figures of the corresponding prevlous period have been regrouped/reclassified wherever necessary, to make them comparable.
6 The results are also available an the webiste of the Company wwfirhlslxom
Place : Hyderabad For DR HABEEBULIAH LIFE SGENEES LIMITED
Bate 2 11/11/2018
K. Krishnam RajuExecutive Chairman (DIN 00814659)
Dr Habeebullah Life Sciences Ltd(Formerly Known as PC Products India Limited)
chd.0fi' : 2-5—36J‘CLRD/l. Chilltalmel X Roads. Upperpally, Rajendra Nagal’ Mandal. Hyderabad a 500048a TS.Indla
Corp 00" : No.11, Phase I, Vasudcva’s Bloomfield Elation. Khajaguda, Nallakramguda, Hyderabad — 500008.TS. India
0. : 1485 l 1 ()TG 1996PLC099198 Email : inlblti2drlllsl.com, pcproductslndialij gmailcomContact [N t.: 040 - 2970 3333, +91 9030057370 Website : wwwdrhlal,cmn
5% or Habeebuflahé Life Saences
Statement of Assets and Liabilities
(INR. in iakhs ]Half Year Ended Year Ended
Particulars 30-09-18 31-03-18
Unaudited Audited
ASSETS
Non Current Assets
Property, Plant and Equipments 3.43 1.99
Capital Work In Progress
Investment Prpoerty
Goodwill
Other lntangable Assets
lntangable Assets under development 153.03 91.66
Biological assets other than bearer plantsFinancial Assets:
Investments 487.06 487.06
Trade Receivables
Loans
Others
Deferred Tax Assets (net)
Other Non Current Assets
Total Non Current Asets 643.53 580.71
Current Assets
Inventories 14.80 9.52
Financial Assets
Investments
Trade Receivables 217.68 287.4
Cash and Cash Equivalents 1.09 33.23
Bank balances other than above 5.86
Loans 96.74 70
Others
Current Tax Assets (net)
Other Current Assets 300.22 241.85
Total Current Assets 636.38 642.00
Total Assets_ 1,279.91 1,222.71
EQUITY AND LIABILITIES
Eguky
Equity Share Capital 1,221.37 1,175.87
Other Equity
Reserves & Surplus (218.05) (142.23)Share warrants 129.75 152.50
Total - Equity 1,133.07 1,186.14
Dr Habeebullah Life Sciences Ltd(Formerly Known as PC Products India Limited)
Regd.()ff : 2-5-36/(TLRD/l. Chintalmet X Roaés. Upperpally. Rajendra Nagar Mandel, Hyderabad - 500048. TS.India
Corp Olf : No.1 1. Phase I. Vasudeva’s Bloomfield Elation. Khajaguda. Nanakramguda, Hyderabad ~ SOUOOSTS. India
CIN N0. : L85110TGI996PLCO99198 Email : infoai drhlsl.c0m. pcproductsindlaaggmaiLeomContact New 040 — 2970 3333, +91 9030057370 Website : www.clrhlsleom
E“ or HabeebullahA Life SCiences
Liabilities
Non Current Liabilities
Financial Liabilities
Borrowings 63.00 '
Trade Payables
Other Financial Liabilities
Provisions
Deferred Tax Liabilities (net)
Other Non Current Liabilities
Total Non Current Liabilities 63.00 —
Current Liabilities
Financial Liabilities
Borrowings
Trade Payables 23.44 621
Other Financial Liabilities
Other Current Liabilities 24.11
Provisions 6041 6.25
Currenr Tax Liabilities (net)
Total Current Liabilities 83.84 3657
Total - Equity and Liabilities 1,279.91 1f222.71
Place : Hyderabad For DR HABEEBULLAH LlFE SCHENCES LIME
Date : 12/11/‘2018
K. Krishnam Raiu
Executive Chairman (BlN 00814650)
Dr Habeebullah Life Sciences Ltd(Formerly Known as PC Products India Limited)
Rengfi‘ : 2<5~36/CLRD/l, (‘hintalmei X Roads, Upperpally, Rajendra Nagar Mandal. Hyderabad » 500048. TS.lndia
Corp Off : No.1] A Phase L Vasudeva‘s Bloomfield Elation Khajaguda. Nanakramguda, Hyderabad — SOOOORTS. India
CIN N0. : L85 1 l OTG l 996PLC099I98 Email : infoQi‘drhlslpom, poproducisindiaqi‘gmail.comContact N .: 040 ~ 2970 3333, +91 9030057370 Website : wwwdrhlsicom
201 E: 202, Floor 2, Manbhum Jade Towers
M S KA 6~3-1090lAr‘12 & i3, Katriya Hotel Lane
Somajiguoa, Hyderabad 500682, lNDlA
Tel: *9! 40 3024 2999
E? Associates
Chartered Accountants
Limited Review Report
Review Report to
The Board of Directors
DR HABEEBULLAH LIFE SCIENCES LIMITED
1. We have reviewed the accompanying statement of unaudited standalone financial results for the
quarter ended 30m September, 2018 and the year to-date results for the period in April 2018 to 30‘h
September, 2018 and financial position as on 30‘“ September, 2018 (‘the Statement’) of DR
HABEEBULLAH LiFE SCIENCES UMITED ('the Company’), being submitted by the Company pursuant to
the requirements of Regulation 33 as modified by Circular No. ClR/CFDIFAC/ 62/2016 dated July 5,2016 and Regulation 52 as modified by Circular No. CIR/ lMD/ DF1/69/2016 dated August 10, 2016 read
with Regulation 63(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (Listing Regulations).This Statement, which is the responsibility of the Company's Management and has been approved bythe Board of Directors, has been prepared in accordance with ind AS 34 ‘Interim Financial Reporting',prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunderand other recognized accounting practices and policies generally accepted in lndia. Our responsibility isto issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Reviewof interim Financial lnfonnation Performed by the independent Auditor of the Entity issued by theInstitute of Chartered Accountants of India. This standard requires that we plan and perform thereview to obtain moderate assurance as to whether the Statement is free of material misstatement. Areview is limited primarily to inquiries of Company personnel and analytical procedures applied to
financial data and thus provide less assurance than an audit. We have not performed an audit and
accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe
that the accompanying Statement of unaudited standalone financial results and financial position whichare prepared in accordance with Ind I6 34, prescribed under Section 133 of the Companies Act, 2013
read with relevant rules issued thereunder and other recognized accounting practices and policies has
not disclosed the information required to be disclosed in terms of the Listing Regulations including themanner in which it is to be disclosed, or that it contains any material misstatement.
For MSKA & Associates (Formerly known as MZSK a Associates)
Ananthakrishnan G WPartner
Membership No.:205226
Place: HyderabadDate: 12‘“ November, 2018
Head office: Floor 3, Enterprise Centre, Nehru Road, Near Domestic Airport, Vile Parle (E), Mumbai 400099, INDIA, Tel: «91 22 3358 9800Sengaiuru l Chennai I Hyderabad l Kolkata l Mumbai 1 New Delhi , Gurugrarn ] Pune mm.mska.in